Short answer
AVANOS MEDICAL, INC. (AVNS) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $182M (up 8.8% year over year) with net income of $5M.
Q1 2026 key financials · XBRL
- Revenue
- $182M
- +8.8% YoY
- Net income
- $5M
- −22.7% YoY
- Operating margin
- 4.9%
- Gross margin
- 51.7%
- EPS (diluted)
- $0.11
- −21.4% YoY
Source: XBRL data from the AVANOS MEDICAL, INC. (AVNS) Q1 2026 10-Q on SEC EDGAR. USD.
AVANOS MEDICAL, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Merger agreement announced April 13, 2026; $25.00-per-share cash consideration
- Quarterly revenue and YoY change not provided in submitted excerpt
- Profitability and segment performance figures not provided in submitted excerpt
- Cash position, operating cash flow, and capital deployment details not provided in submitted excerpt
Risk Factors
- Newly added merger risk triggered by April 13, 2026 Merger Agreement
- Regulatory and approval risk from required regulatory clearances and majority stockholder approval
- Operational disruption risk from employee attrition and customer or supplier delays during merger uncertainty
- Competitive transaction risk from no-shop restrictions limiting superior acquisition proposals
- Financial exposure from $37,500,000 termination fee under specified circumstances
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other AVANOS MEDICAL, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.